These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 24124823)
1. Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: lack of lasting improvement or cure in the majority of patients. Spring P; Spanou Z; de Viragh PA J Am Acad Dermatol; 2013 Nov; 69(5):830-832. PubMed ID: 24124823 [No Abstract] [Full Text] [Related]
2. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Mirmirani P; Karnik P Arch Dermatol; 2009 Dec; 145(12):1363-6. PubMed ID: 20026843 [TBL] [Abstract][Full Text] [Related]
4. Use of pioglitazone in patients with lichen planopilaris. Baibergenova A; Walsh S J Cutan Med Surg; 2012; 16(2):97-100. PubMed ID: 22513061 [TBL] [Abstract][Full Text] [Related]
5. The use of oral pioglitazone in the treatment of lichen planopilaris. Mesinkovska NA; Tellez A; Dawes D; Piliang M; Bergfeld W J Am Acad Dermatol; 2015 Feb; 72(2):355-6. PubMed ID: 25592345 [No Abstract] [Full Text] [Related]
6. The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease. Hanyu H; Sato T; Sakurai H; Iwamoto T J Am Geriatr Soc; 2010 May; 58(5):1000-1. PubMed ID: 20722838 [No Abstract] [Full Text] [Related]
8. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Werner C; Kamani CH; Gensch C; Böhm M; Laufs U Diabetes; 2007 Oct; 56(10):2609-15. PubMed ID: 17623816 [TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-Mesenchymal Stem Cell Transition in a Human Organ: Lessons from Lichen Planopilaris. Imanishi H; Ansell DM; Chéret J; Harries M; Bertolini M; Sepp N; Bíró T; Poblet E; Jimenez F; Hardman J; Panicker SP; Ward CM; Paus R J Invest Dermatol; 2018 Mar; 138(3):511-519. PubMed ID: 29106928 [TBL] [Abstract][Full Text] [Related]
11. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. Brzozowski T; Konturek PC; Pajdo R; Kwiecień SN; Konturek S; Targosz A; Burnat G; Cieszkowski J; Pawlik WW; Hahn EG Inflammopharmacology; 2005; 13(1-3):317-30. PubMed ID: 16259750 [TBL] [Abstract][Full Text] [Related]
12. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
13. The peroxisome proliferator-activated receptor γ agonist pioglitazone prevents NF-κB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway. Zhang J; Zhang Y; Xiao F; Liu Y; Wang J; Gao H; Rong S; Yao Y; Li J; Xu G Biochem Pharmacol; 2016 Feb; 101():100-11. PubMed ID: 26673543 [TBL] [Abstract][Full Text] [Related]
14. Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. Kashiwagi Y; Mizuno Y; Harada E; Shono M; Morita S; Yoshimura M; Yano M; Yasue H Am J Med Sci; 2013 Jun; 345(6):497-500. PubMed ID: 23313950 [TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Shukla DK; Kaiser CC; Stebbins GT; Feinstein DL Neurosci Lett; 2010 Mar; 472(3):153-6. PubMed ID: 20144689 [TBL] [Abstract][Full Text] [Related]
16. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial. Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Ibrahim K; Strasser RH; Braun-Dullaeus RC Cardiology; 2015; 131(3):165-71. PubMed ID: 25967848 [TBL] [Abstract][Full Text] [Related]
17. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472 [TBL] [Abstract][Full Text] [Related]
18. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631 [TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Nagahama R; Matoba T; Nakano K; Kim-Mitsuyama S; Sunagawa K; Egashira K Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2427-34. PubMed ID: 22879581 [TBL] [Abstract][Full Text] [Related]
20. Letter: Iatrogenic lipomatosis: a rare manifestation of treatment with a peroxisome proliferator-activated receptor gamma agonist. Femia A; Klein PA Dermatol Online J; 2010 Apr; 16(4):15. PubMed ID: 20409422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]